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Abstract
Our developmental studies provide an insight into the pathogenesis of heart failure in adults. These 
studies reveal a mechanistic link between fetal cardiomyocytes and pathologically stressed adult 
cardiomyocytes at the level of chromatin regulation. In embryos, chromatin-regulating factors 
within the cardiomyocytes respond to developmental signals to program cardiac gene expression 
to promote cell proliferation and inhibit premature cell differentiation. In the neonatal period, the 
activity of these developmental chromatin regulators is quickly turned off in cardiomyocytes, 
coinciding with the cessation of cell proliferation and advance in cell differentiation toward adult 
maturity. When the mature hearts are pathologically stressed, those chromatin regulators essential 
for cardiomyocyte development in embryos are reactivated, triggering gene reprogramming to a 
fetal-like state and pathological cardiac hypertrophy. Furthermore, in the study of chromatin 
regulation and cardiac gene expression, we identified a long noncoding RNA that interacts with 
chromatin remodeling factor to regulate the cardiac response to environmental changes. This 
article is part of a Special Issue entitled: Cardiomyocyte Biology: Integration of Developmental 
and Environmental Cues in the Heart edited by Marcus Schaub and Hughes Abriel.
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1. Introduction
The genetic information is encoded by DNA sequence, and epigenetic alternations of 
chromatin can regulate the expression of genetic information. Chromatin is evolved to 
associate DNA with histone proteins, providing a scaffold to package the long 1.7-meter 
DNA strands into a small 6-μm nucleus. The basic packaging unit of chromatin is the 
nucleosome, which contains ~147 bp DNA enveloping an octamer core of histones (two 
molecules of each of the canonical H2A, H2B, H3 and H4 histones) (Fig. 1). Chemical 
interactions between histones and DNA, as well as the position of nucleosomes in the 
genome, can alter the accessibility of DNA sequence to transcription regulation. These 
changes of chromatin are mediated by three major mechanisms: covalent modifications of 
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histone protein side chains, covalent modifications of DNA bases, and non-covalent changes 
of the composition and positioning of nucleosomes (Fig. 1) [1]. Such covalent and non-
covalent changes of nucleosomes enable the chromatin scaffold to respond to environmental 
signals to modulate gene expression and alter the physiological state of cells.
Histones can be modified by various histone-modifying enzymes that catalyze methylation, 
acetylation, or other chemical processes, whereas the cytosine base of DNA can be 
methylated by DNA methyltransferases. On the other hand, the position and histone 
composition (canonical vs non-canonical histones) of nucleosomes are regulated by a group 
of ATP-dependent nucleosome/chromatin-remodeling complexes. A critical component of 
the chromatin-remodeling complex is the ATPase subunit, which hydrolyzes ATP to 
mobilize nucleosomes or change their histone composition. In vertebrates, there are four 
families of chromatin-remodeling complexes defined by the evolutionarily conserved 
ATPase subunit: SWI/SNF (Switch defective/sucrose nonfermenting), ISWI (imitation 
switch), and CHD (chromodomain, helicase, DNA binding), and INO80 (inositol requiring 
80) (reviewed in [2–5]). Each ATPase protein consists of a conserved catalytic domain (for 
ATP hydrolysis) and various functional domains that recognize modified histones, regulate 
ATP catalytic activity, or mediate protein–protein interactions. These specific domains 
characterize the ATPase from each of the four families of chromatin-remodeling complexes.
Recent studies revealed that long-noncoding RNAs (lncRNAs) can partner with or 
counteract epigenetic regulators to control chromatin and gene expression. lncRNAs are 
defined as non-peptide/protein-coding RNA transcripts that are longer than 200 nucleotides, 
and these RNAs are largely discovered by next generation sequencing-based transcriptome 
profiling. The expression of lncRNAs is highly tissue-specific and is dynamically regulated 
by environmental cues from physiological signals or pathological stimuli. lncRNA 
promoters are enriched with histone 3 lysine 4 trimethylation (H3K4me3), RNA polymerase 
II (Pol II), and DNase I hypersensitivity sites [6], suggesting active tissue regulation of 
lncRNA expression. However, it remains largely unknown how lncRNAs function in vivo 
and how they are regulated.
lncRNAs have biochemical abilities to interact with a wide range of molecules to form 
RNA–RNA, RNA–DNA, or RNA–protein complexes [7]. With this capacity, lncRNAs show 
broad associations with the epigenetic machinery to control covalent modifications of 
chromatin [8–10]. More recently, the epigenetic roles of lncRNAs are extended to the 
regulation of non-covalent nucleosome remodeling process through a direct physical 
interaction with the ATP-dependent chromatin-remodeling factor [11]. Here, we use the 
chromatin remodeler Brg1 and cardiac-specific lncRNA Myheart (Mhrt) as an example to 
illustrate how cardiomyocytes respond to pathophysiological signals by changing the 
chromatin-remodeling factor–lncRNA interactions to reprogram gene expression.
1.1. Pathophysiological roles of Brg1 in heart development and disease
Brg1 is an essential ATPase component of the SWI/SNF-like BAF (brahma-associated 
factor) chromatin-remodeling complex. In embryos, the Brg1/BAF complex responds to 
developmental signals to regulate the proliferation and differentiation of fetal 
cardiomyocytes [12]. Tissue-specific disruption of Brg1 in fetal cardiomyocytes results in 
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abnormal heart development with thin myocardium and absence of interventricular septum 
[12]. These mutant embryos die around embryonic day 11.5 (E11.5) [12], likely due to 
pump failure of the heart. In fetal cardiomyocytes, Brg1 promotes cell proliferation by 
maintaining Bmp10 and suppressing p57kip2 (Cdkn1c) expression [12]. Bmp10 is a 
cardiomyocyte growth factor [13], whereas p57kip2 is a cyclin-dependent kinase inhibitor 
that suppresses cell cycle progression. In embryonic hearts, Bmp10 is abundantly expressed 
in cardiomyocytes, and there is no p57kip2 expression. In the absence of Brg1, Bmp10 
expression is compromised, with p57kip2 ectopically expressed in cardiomyocytes to inhibit 
cell proliferation, leading to thin myocardium and absence of interventricular septum. 
Restoration of Bmp10 in Brg1 mutants rescues such cardiomyocyte proliferation defects. 
The Brg1– Bmp10 pathway is therefore an essential mechanism that respond to 
developmental signals to control cardiomyocyte proliferation. Brg1 does not regulate Bmp10 
expression at the promoter level [12], suggesting that Brg1 may signal through certain 
genetic pathways to control Bmp10. The exact mechanism of how Brg1 maintains Bmp10 
expression in developing cardiomyocytes will require further investigations.
Although the Brg1-null cardiomyocytes fail to proliferate, these cells undergo premature 
differentiation, as evidenced by increased thickness and segmentation of myofibrils and by 
gene expression switch from fetal to adult isoform, such as the switch from predominantly 
β-myosin heavy chain (β-MHC or Myh7) to predominantly -MHC (Myh6) expression [12]. 
In mice, Myh6 is the dominant isoform of the MHC molecular motor gene expressed in 
adult heart ventricles, while Myh7 is the primary isoform in embryonic ventricles. In 
response to developmental signals that trigger cardiomyocyte proliferation, Brg1 suppresses 
premature differentiation of fetal cardiomyocytes. Within fetal cardiomyocytes, Brg1 
complexes with histone deacetylase (HDAC) and poly (ADP ribose) polymerases (PARP) on 
the promoters of Myh genes to concurrently repress Myh6 and activate Myh7 expression 
[12]. The Brg1/HDAC/PARP chromatin complex thus maintains an expression of the fetal 
isoform of MHC in developing cardiomyocytes to preserve the fetal state of cardiomyocyte 
differentiation.
In fetal cardiomyocytes, Brg1 controls cell proliferation and differentiation in parallel 
through two independent pathways [12]. In whole embryo culture studies, recombinant 
Bmp10 proteins rescue the proliferation defects of Brg1-null cardiomyocytes, without 
changing the premature switch to Myh6 expression in those cells. Conversely, 
pharmacological inhibition of HDAC or PARP in cultured wild-type embryos produces the 
premature Myh switch but without affecting cardiomyocyte proliferation. These 
observations suggest that Brg1 governs two independent pathways (Bmp10 and HDAC/
PARP) to simultaneously control fetal cardiomyocyte proliferation and differentiation. Brg1 
therefore serves as a critical switch that is turned on by developmental signals to control 
cardiomyocyte proliferation and differentiation.
Although highly expressed in the fetal heart, Brg1 is down-regulated in the neonatal heart 
[12], coinciding with the physiological Myh7-to-Myh6 switch and the maturation of fetal 
cardiomyocyte into postmitotic, highly-differentiated adult cardiomyocytes. The molecular 
actions of Brg1 in fetal cardiomyocytes suggest that such Brg1 turnoff in the neonatal period 
is essential for neonatal cardiomyocytes to cease proliferation and undergo differentiation to 
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become mature cardiomyocytes. The mature adult hearts express low level of Brg1 in 
cardiomyocytes; however, when the mature cardiomyocytes are pathologically stressed, 
Brg1 expression is reactivated, triggering pathological Myh6-to-Myh7 switch and adverse 
cardiac remodeling with hypertrophy and interstitial fibrosis [12]. Genetic disruption of 
Brg1 in stressed cardiomyocytes prevents the development of cardiac hypertrophy, fibrosis, 
and failure. Once reactivated by cardiac stress, Brg1 complexes with its embryonic partners 
HDAC and PARP, and this complex binds to Myh promoters to simultaneously repress 
Myh6 and activate Myh7 as it does in fetal cardiomyocytes. Besides triggering pathological 
Myh switch, Brg1 binds to the promoter and activates the expression of Osteopontin (Opn), 
a pro-fibrotic factor secreted by cardiomyocytes to induce tissue fibrosis [11]. Brg1 also 
triggers the switch from a predominant fatty acid to glucose metabolism in the stressed 
hearts by controlling the expression of many metabolic genes (Chang lab, unpublished data). 
All these Brg1-mediated changes of gene expression in the stressed hearts contribute to the 
development of pathological hypertrophy and heart failure. BRG1 expression also increases 
in human hypertrophic hearts, with BRG1 level correlating strongly with the degree of 
pathological MYH switch and the severity of hypertrophy [12]. The mouse and human tissue 
studies suggest an evolutionarily conserved Brg1-mediated mechanism in human heart 
disease.
1.2. Stress-induced chromatin changes in the heart
Brg1 is a chromatin remodeler that is induced environmental stress to reprogram cardiac 
gene expression and trigger hypertrophy and heart failure [12]. The stress-induced assembly 
of three classes of chromatin-regulating factors—Brg1, HDAC, and PARP—on the Myh 
gene promoters suggests that chromatin is a place where stress-response signals converge to 
reprogram gene expression. However, it remains largely unknown how chromatin-regulating 
factors act in concert to modulate chromatin scaffold in the heart. The Myh6 and Myh7 gene 
loci, antithetically regulated under different pathophysiological conditions, contain crucial 
information about epigenetic regulation of cardiac gene expression. Encoded within the Myh 
gene loci are the cardiac epigenetic regulator miR208a (within Myh6 loci) [15–17], 
miR208b (within Myh7 loci) [18], and Myheart (within Myh7 loci) [11] (Fig. 2a). Further 
analysis of chromatin scaffold changes of Myh6 loci at different pathophysiological states 
revealed two new classes of chromatin modifiers—G9a/GLP histone methyltransferase and 
DNA methyltransferase (DNMT)—that are necessary for stress-induced cardiac hypertrophy 
and failure (Chang lab, unpublished results). In mouse hearts, G9a/Glp and Dnmt3 have 
expression patterns similar to that of Brg1: they are highly expressed in fetal hearts, their 
expression down-regulated in mature adult hearts but reactivated in pathologically stressed 
hearts. Once activated in stressed hearts, Brg1, G9a/Glp, and Dnmt3 proteins form a 
physical complex in the cardiomyocytes. Brg1 sequentially recruits G9a/Glp and Dnmt3 to 
Myh6 (but not Myh7) promoter to assemble a repressive chromatin scaffold, composed of 
methylated histone 3 lysine 9 (H3K9) catalyzed by G9a/Glp as well as methylated CpG 
dinucleotides catalyzed by Dnmt3. This repressive chromatin silences Myh6 expression in 
stressed hearts, contributing to the decline of cardiac contractility.
Genetic disruption of G9a/Glp or Dnmt3a in mouse adult cardiomyocytes or 
pharmacological inhibition of G9a/Glp or Dnmt reduces the repressive chromatin marks on 
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Myh6, lessens cardiac hypertrophy, and prevents the decline of heart function. The 
repressive chromatin assembly on Myh6 loci requires sequential molecular interactions 
between Brg1, G9a/Glp, and Dnmt3. Brg1 first recruits G9a/Glp, which then recruits Dnmt3 
to the Myh6 promoter to successively catalyze histone and DNA methylation. G9a/GLP and 
DNMT, like BRG1, are also increased in human hypertrophic hearts, and their expression 
levels correlate with disease severity and with the degree of H3K9 and CpG methylation of 
Myh6 promoter. These findings suggest a conserved chromatin mechanism in human 
cardiomyopathy.
Brg1-governed sequential recruitment of G9a/Glp and Dnmt3 to Myh6 loci demonstrates a 
new mechanistic link from chromatin-remodeling factor to H3K9 and CpG methylation, 
which is critical for the pathogenesis of heart failure. The repressive chromatin environment 
on Myh6 promoter is created by at least five different classes of chromatin-regulating 
factors: Brg1, G9a/GLP, Dnmt3, Hdac, and Parp [12] (Chang lab, unpublished results). 
Among these factors, only the expression of Brg1, G9a/Glp, and Dnmt3—but not Hdac 
(Hdac1, 2, 3) or Parp1—is activated by pathological stress in mouse or human hearts. To 
further define the chromatin mechanism that responds to environmental cues, it will be 
important to identify new components of the stress-induced epigenetic complex and 
determine how these components biochemically cooperate to target specific genomic sites to 
orchestrate cardiac epigenomic response to environmental stress.
1.3. Genome-targeting mechanism of Brg1 in the heart
It is physiologically crucial for chromatin-remodeling complexes to localize to specific 
regions of the genome to coordinate gene expression [2]; however, the targeting mechanism 
of chromatin-remodeling complexes is largely undefined. Our studies showed a new 
targeting mechanism encoded within the ATPase subunit of chromatin-remodeling 
complexes [11]. We found that the helicase domain (also known as ATPase domain) of Brg1 
is crucial for Brg1 to bind to its genomic target sites to control cardiac gene expression [11]. 
This evolutionarily conserved helicase domain belongs to the Deadbox RNA helicase 
subfamily of the superfamily 2 (SF2) helicase [2,19–21]. It consists of two homologous 
“RecA-like” domains (D1 and D2), which fold upon each other to form two clefts that bind 
ATP on one side and RNA nucleotides on the other. This structure couples ATP hydrolysis 
and RNA unwinding [22,23]. ATP hydrolysis by this ATPase/helicase domain is essential for 
driving chromatin remodeling activity of the BAF complex. However, how this same domain 
anchors Brg1 to the chromatin targets is previously unknown. Molecular and biochemical 
studies showed that this Brg1 helicase domain has dual nucleotide-binding specificities: it is 
capable of binding RNA and chromatinized DNA. In the hearts or cultured cells, Brg1 
requires this domain to target to its downstream gene promoters to regulate gene expression. 
Disruption of the helicase domain prevents Brg1 from binding to its target sites to execute 
chromatin remodeling and gene regulation. Interestingly, both biochemical and cell-based 
as-says showed that Brg1 helicase domain can only bind to DNA that is chromatinized or 
histone-bound, but not to the naked DNA. The structural basis of how this domain 
distinguishes naked from chromatinized DNA is still unknown. In the studies of Brg1 and 
Myh expression regulation, we uncovered a cardiac-specific lncRNA (Mhrt) encoded within 
the Myh genomic loci. This lncRNA can disrupt the helicase-based targeting mechanism to 
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inhibit Brg1’s chromatin activity and protect the heart from pathological hypertrophy (Fig. 
2b) [11].
1.4. lncRNA and chromatin remodeling in stressed hearts
lncRNAs are known to be associated with human heart disease. These RNAs include MIAT 
(myocardial infarction associated transcript) [24], ANRIL (Antisense non-coding RNA of 
INK4/ARF locus) [25–27], KCNQ1OT1 (KCNQ1 opposite strand/antisense transcript 1) 
[28], LIPCAR (mitochondrially encoded long non-coding cardiac associated RNA) [29], and 
Myheart (Myosin heavy chain associated RNA transcript) [11]. lncRNA profiling from 
cardiac tissues of patients with left ventricular assistance device suggested that lncRNA 
signatures can predict the clinical outcome of these patients [30]. The mechanisms of these 
disease-associated lncRNAs are obscure.
The Myh-associated RNA transcripts or Myheart (Mhrt) represent a cluster of alternatively 
spliced nuclear lncRNA transcripts that are encoded within the Myh genomic loci [11]. 
These RNAs are transcribed from the promoter of Myh6 in an antisense direction into the 
genomic site of Myh7. In the adult mouse tissues, Mhrt is predominantly expressed in the 
heart with no or minimal expression in other tissues. In embryonic hearts Mhrt transcripts 
are expressed at low levels, and its abundance increases as the heart matures to adulthood. 
When the adult mouse heart is pathologically stressed, Mhrt expression is suppressed, and 
such suppression is essential for the development of heart failure. Transgenic restoration of 
Mhrt expression in stressed mouse cardiomyocytes prevents the heart from developing 
pathological hypertrophy and failure, indicating a cardioprotective role of Mhrt against 
environmental stress (Fig. 2b). In Mhrt-rescued hearts, Mhrt directly reverses Brg1-mediated 
pathological Myh switch and activation of the profibrotic Opn. Biochemical, cell-based, and 
genetic studies showed that Mhrt directly binds to the helicase domain of Brg1 to compete 
with chromatinized DNA for the binding of Brg1 (Fig. 2c). As a result, when Mhrt 
expression is transgenically restored in the stressed hearts, Brg1 is unable to find its target 
gene promoters, including Myh6, Myh7, and Opn [11]. Such removal of Brg1 from its gene 
targets alters gene expression in the stressed hearts. The helicase’s dual-binding specificity 
for nucleotides (RNA and chromatinized DNA) not only enables Brg1 to target the genome, 
but also allows such targeting by chromatin remodelers to be regulated by lncRNAs in 
response to environmental cues.
2. Discussion
The opposite regulations of Myh6 and Myh7 by the Brg1 complex can be caused at least by 
two different processes. The first one involves differential recruitment of chromatin 
regulators by Brg1 to Myh promoters. For example, Brg1 recruits the chromatin repressor 
G9a and Dnmt3 on Myh6 promoter, but not Myh7 promoter. This is associated with 
increased repressive chromatin marks on Myh6 promoter—H3K9me2 (catalyzed by G9a) 
and methylated CpG (catalyzed by Dnmt3)—causing its repression. These chromatin factor 
and histone mark changes provide a partial explanation for the differential regulation of 
Myh6 and Myh7. The epigenetic factor recruitment involves protein–protein interactions and 
may require additional information from local epigenetic landscape and/or DNA sequence. 
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The second process is related to differential recruitment of transcription factors to Myh sites. 
YY1 is known to repress Myh6 expression, whereas NFAT1 and AP-1 are activators for 
Myh7 [31–34]. Brg1 may recruit different transcription repressors or activators to Myh sites 
to execute differential gene control. The transcription factor recruitment may require DNA 
sequence information. Further studies are needed to decipher how Brg1 interacts with 
epigenetic and transcription factors as well as with local DNA sequence to control the Myh 
promoters.
Brg1 and Mhrt form a feedback circuit in the heart, and such molecular circuit can be 
perturbed by environmental stress to cause cardiac hypertrophy and failure (Fig. 2b) [11,12]. 
Mhrt is capable of suppressing Brg1’s activity in normal hearts to protect the hearts from 
aberrant activities of Brg1. However, pathological stress activates the expression of Brg1, 
which then forms a repressive chromatin complex with HDAC and PARP to inhibit Mhrt 
expression, resulting in aberrant gene reprograming and heart failure. In normal hearts, Brg1 
level is too low to overcome its suppression by the abundant Mhrt. Conversely, in stressed 
hearts, the level of Brg1 is much enhanced, allowing Brg1 to over-run Mhrt to gain its 
chromatin targeting to the Mhrt promoter and shut down Mhrt expression. The more Mhrt is 
shutdown, the further gain of Brg1 activity to turn off Mhrt, thus constituting a positive-
feedback molecular competition that tips the balance toward Brg1 dominance in hearts that 
experience sustained environmental stress. The dose–dependent interactions among Brg1, 
Mhrt, and Mhrt promoter were demonstrated biochemically and in cell-based studies [11], 
providing a molecular basis for the pathogenesis of sustained environmental stress. 
Moreover, this positive Brg1–Mhrt feedback loop suggests the existence of a Brg1 
expression threshold that converts a heart from a healthy into a disease state. Expression 
studies of Brg1 in hypertrophic human hearts are consistent with such threshold effect of 
Brg1 in triggering heart disease [12]. The chromatin–lncRNA interactions thus exemplify an 
epigenetic regulatory mechanism by which cardiomyocytes respond to environmental 
signals.
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b and c. Brg1, the ATPase subunit of BAF chromatin-remodeling complex, binds to its 
genomic targets through the helicase domain. Brg1 expression is activated by cardiac 
stress, and in stressed hearts Brg1 binds to Mhrt promoter to repress its expression (b). 
Conversely, Mhrt can bind to Brg1 helicase domain to prevent Brg1 from binding to its 
genomic targets (c). This reciprocal inhibition constitutes a molecular feedback circuit to 
maintain cardiac homeostasis.
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Chromatin structure and major regulatory mechanisms. DNA is packaged by nucleosome 
units, each composed of ~147 bp of DNA (blue line) that wrap around histones (yellow). 
Such chromatin structure is controlled by three major regulatory mechanisms. Chromatin 
remodelers control the composition and position of nucleosomes. Histone modifiers catalyze 
covalent modifications of histones, which are recognized by histone readers. DNA 
modifiers, primarily DNA methyltransferases, are responsible for DNA methylation.
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Molecular feedback circuit between Mhrt and Brg1. a. Relative genomic location of Myh6, 
Myh7, and Mhrt. All three genes are regulated by Brg1.
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